About Us: Approach

EMPOWERING A NEW MODEL OF DRUG DEVELOPMENT

Drug development has reached an inflection point. Legacy drug development models are falling short in meeting those needs. Aditum Bio is dedicated to filling the gap through an alternative, patient-driven approach to acquiring and developing novel drug assets.

FULLFILLING THE PROMISE OF SCIENCE

Genetic, genomic and artificial intelligence have led to the discovery of new drug targets and therapeutic modalities; however, many drug candidates fail to be developed due to strategic decisions and high clinical trial expense. Aditum Bio stands apart in the biotech venture capital arena through our differentiated approach for identifying promising, clinic-ready therapies that offer value for underserved patient populations, in areas such as obesity, depression, substance abuse, renal disease, and infectious diseases.

lab011933x1400.jpg
ACCELERATING BIOTECH COMPANY FORMATION

Harnessing our experienced in-house R&D domain experts as the foundation of our agile operating model, Aditum Bio is able to accelerate the formation and ramp-up of its portfolio companies. We augment each company's newly-established, dedicated leadership team with medical and scientific experts. Operating under the Aditum Bio umbrella in a lean and efficient management structure, portfolio companies are empowered to rapidly progress newly-acquired drug candidates into Phase 2 clinical trials. 

Aditum Bio LEVERAGING TECHNOLOGY.jpg

LEVERAGING TECHNOLOGY FOR EFFICIENT TRIAL EXECUTION

Aditum Bio’s strategic advantage extends to its proven acumen for using an array of powerful technologies and digital tools throughout its portfolio companies to support clinical trial execution at the highest level of efficiency. Through our in-house technology capabilities and our extensive partnerships with leading solutions providers, we enable therapies to advance more quickly and at lower cost than in traditional R&D models.